恒瑞医药：SHR-9539注射液、HRS-3738片获药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for clinical trials of SHR-9539 injection and HRS-3738 tablets, marking a significant step in its drug development pipeline [1] Group 1: SHR-9539 Injection - SHR-9539 injection is a Class 1 therapeutic biological product that targets multiple myeloma cells by recruiting and activating T cells [1] - Currently, there are no similar drugs approved for market in China [1] - The cumulative R&D investment for the SHR-9539 injection project is approximately 39.93 million yuan [1] Group 2: HRS-3738 Tablets - HRS-3738 tablets are a next-generation CRBNE3 ubiquitin ligase modulator that affects the proliferation of hematological tumor cells by degrading specific substrates [1] - The drug has strong substrate degradation capabilities and potential advantages in overcoming drug resistance [1] - There are no similar drugs approved for market domestically or internationally [1] - The cumulative R&D investment for the HRS-3738 tablet project is approximately 63.63 million yuan [1]